Literature DB >> 22179188

Long-term follow-up of EBV-positive lymphoproliferative disorders in a patient with systemic lupus erythematosus.

Norifumi Tsukamoto1, Hiroshi Handa, Akihiko Yokohama, Takeki Mitsui, Takayuki Saitoh, Hiromi Koiso, Hideki Uchiumi, Takumi Hoshino, Masamitsu Karasawa, Hirokazu Murakami, Masaru Kojima, Yoshihisa Nojima.   

Abstract

We report a woman in her early thirties with a long-term history of systemic lupus erythematosus (SLE) and prednisolone administration, who progressed to Epstein-Barr virus (EBV)-positive lymphoproliferative disorder (LPD). Treatment for SLE consisted of 1 mg/kg/ day prednisolone followed by 5 mg/day of maintenance therapy. Lymph node biopsies were performed when the patient was in her early thirties, mid-forties, and late fifties. Histologically, the initial lymph node lesion was characterized by numerous enlarged, coalescing lymphoid follicles. The second biopsy showed effacement of the follicles and expansion of the paracortical area. A polymorphous population of small- to medium-sized lymphocytes, plasma cells, and immunoblasts had diffusely infiltrated the paracortical area. In the third lymph node biopsy, fibrous collagen bands divided the epithelioid cell granulomas into nodules. There were numerous Hodgkin and Reed-Sternberg cells in the epithelioid cell granuloma. In situ hybridization demonstrated there were no EBV-infected lymphocytes in the first biopsy; however, EBER(+) cells were detected in the second and third biopsy specimens. The current findings illustrate the natural progression in a patient with a long-term history of EBV(+) B-cell LPD in which the immunodeficiency was caused by SLE and probably her aging, which together resulted in histological change.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22179188     DOI: 10.1007/s00795-011-0551-6

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.070


  16 in total

1.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Anders Osterborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier-Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noel Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

2.  Immunosuppression, autoimmunity, and lymphoproliferative disorders.

Authors:  G Frizzera
Journal:  Hum Pathol       Date:  1994-07       Impact factor: 3.466

3.  Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity.

Authors:  Yoshie Shimoyama; Naoko Asano; Masaru Kojima; Satoko Morishima; Kazuhito Yamamoto; Takashi Oyama; Tomohiro Kinoshita; Shigeo Nakamura
Journal:  Pathol Int       Date:  2009-12       Impact factor: 2.534

4.  The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.

Authors:  Sarah Park; Jeeyun Lee; Young Hyeh Ko; Arum Han; Hyun Jung Jun; Sang Chul Lee; In Gyu Hwang; Yeon Hee Park; Jin Seok Ahn; Chul Won Jung; Kihyun Kim; Yong Chan Ahn; Won Ki Kang; Keunchil Park; Won Seog Kim
Journal:  Blood       Date:  2007-03-30       Impact factor: 22.113

5.  The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.

Authors:  M A Nalesnik; R Jaffe; T E Starzl; A J Demetris; K Porter; J A Burnham; L Makowka; M Ho; J Locker
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

Review 6.  Immunodeficiency-associated lymphomas.

Authors:  Huy Tran; Jamie Nourse; Sara Hall; Michael Green; Lyn Griffiths; Maher K Gandhi
Journal:  Blood Rev       Date:  2008-05-05       Impact factor: 8.250

7.  Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression.

Authors:  O W Kamel; M van de Rijn; D P LeBrun; L M Weiss; R A Warnke; R F Dorfman
Journal:  Hum Pathol       Date:  1994-07       Impact factor: 3.466

8.  Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.

Authors:  Takashi Oyama; Kazuhito Yamamoto; Naoko Asano; Aya Oshiro; Ritsuro Suzuki; Yoshitoyo Kagami; Yasuo Morishima; Kengo Takeuchi; Toshiyuki Izumo; Shigeo Mori; Koichi Ohshima; Junji Suzumiya; Naoya Nakamura; Masafumi Abe; Koichi Ichimura; Yumiko Sato; Tadashi Yoshino; Tomoki Naoe; Yoshie Shimoyama; Yoshikazu Kamiya; Tomohiro Kinoshita; Shigeo Nakamura
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

Review 9.  Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma.

Authors:  Shigeru Kusumoto; Yasuhito Tanaka; Masashi Mizokami; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2009-06-23       Impact factor: 2.490

10.  Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood.

Authors:  Uk Yeol Moon; Su Jin Park; Sang Taek Oh; Wan-Uk Kim; Sung-Hwan Park; Sang-Heon Lee; Chul-Soo Cho; Ho-Youn Kim; Won-Keun Lee; Suk Kyeong Lee
Journal:  Arthritis Res Ther       Date:  2004-05-07       Impact factor: 5.156

View more
  1 in total

Review 1.  Lupus and Epstein-Barr.

Authors:  Judith A James; Julie M Robertson
Journal:  Curr Opin Rheumatol       Date:  2012-07       Impact factor: 5.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.